Mitochondrial Import and Accumulation of Alpha-synuclein Impair Complex I in Human Dopaminergic Neuronal Cultures and Parkinson Disease Brain
Overview
Authors
Affiliations
Alpha-synuclein, a protein implicated in the pathogenesis of Parkinson disease (PD), is thought to affect mitochondrial functions, although the mechanisms of its action remain unclear. In this study we show that the N-terminal 32 amino acids of human alpha-synuclein contain cryptic mitochondrial targeting signal, which is important for mitochondrial targeting of alpha-synuclein. Mitochondrial imported alpha-synuclein is predominantly associated with the inner membrane. Accumulation of wild-type alpha-synuclein in the mitochondria of human dopaminergic neurons caused reduced mitochondrial complex I activity and increased production of reactive oxygen species. However, these defects occurred at an early time point in dopaminergic neurons expressing familial alpha-synuclein with A53T mutation as compared with wild-type alpha-synuclein. Importantly, alpha-synuclein that lacks mitochondrial targeting signal failed to target to the mitochondria and showed no detectable effect on complex I function. The PD relevance of these results was investigated using mitochondria of substantia nigra, striatum, and cerebellum of postmortem late-onset PD and normal human brains. Results showed the constitutive presence of approximately 14-kDa alpha-synuclein in the mitochondria of all three brain regions of normal subjects. Mitochondria of PD-vulnerable substantia nigra and striatum but not cerebellum from PD subjects showed significant accumulation of alpha-synuclein and decreased complex I activity. Analysis of mitochondria from PD brain and alpha-synuclein expressing dopaminergic neuronal cultures using blue native gel electrophoresis and immunocapture technique showed the association of alpha-synuclein with complex I. These results provide evidence that mitochondrial accumulated alpha-synuclein may interact with complex I and interfere with its functions.
Moore J, Wu T, Dhindsa J, El Fadel O, Le A, Perez A NPJ Parkinsons Dis. 2025; 11(1):46.
PMID: 40069190 PMC: 11897226. DOI: 10.1038/s41531-025-00899-z.
Bochkova Z, Baizhumanov A, Yusipovich A, Morozova K, Nikelshparg E, Fedotova A Biophys Rev. 2025; 17(1):55-88.
PMID: 40060020 PMC: 11885220. DOI: 10.1007/s12551-025-01270-5.
Hu D, Sun X, Qi X bioRxiv. 2025; .
PMID: 40027699 PMC: 11870492. DOI: 10.1101/2025.02.16.638540.
Banerjee I, Das A, Biggs M, Phan C, Cutter L, Ren A Biomimetics (Basel). 2025; 10(2).
PMID: 39997105 PMC: 11852371. DOI: 10.3390/biomimetics10020082.
Parkinson's disease and glucose metabolism impairment.
Chen L, Wang C, Qin L, Zhang H Transl Neurodegener. 2025; 14(1):10.
PMID: 39962629 PMC: 11831814. DOI: 10.1186/s40035-025-00467-8.